Caroline Berube

Hematologist

Medical oncologist, Leukemia specialist

Hematology Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Anticoagulation Clinic

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-725-4932
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Board Certification: Medical Oncology, Royal College of Physicians and Surgeons of Canada (1990)

Board Certification: Hematology, Royal College of Physicians and Surgeons (1989)

Board Certification: Internal Medicine, Royal College of Physicians and Surgeons of Canada (1988)

Residency: Laval University (1987) Canada

Internship: Laval University (1984) Canada

Fellowship: McMaster University (1991) Canada

Fellowship: The University of British Columbia (1990) Canada

Oncology, University of BC, Canada, Medical Oncology (1990)

Board certification, Hematology, Canadian Hematology Board (1989)

Fellowship: University of Montreal (1989) Canada

Hematology, University of Montreal, Canada, Hematology (1989)

Medical Education: Laval University (1983) Canada

F.R.C.P.(C), Internal Medicine, Canadian Board (1987)

M.D., Laval University, Canada, Medicine (1984)

Administrative Appointments

Medical Director, Oral Anticoagulation Clinic, Stanford Hospital and Clinics, 2004

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Hospital & Clinics patient, you have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., & Medeiros, B. C. (2013). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica, 98(4), 591-596.

Accessory splenules in autoimmune hemolytic anemia
Logan, A., Berube, C., & Gotlib, J. (2013). Accessory splenules in autoimmune hemolytic anemia. AMERICAN JOURNAL OF HEMATOLOGY, 88(2), 156-156.

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., & Medeiros, B. C. (2012). Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. LEUKEMIA, 26(5), 893-901.

Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., & Coutre, S. E. (2012). Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 30-37.

Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer
Lee, R., Wen, A., & Berube, C. (2011). Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 68(9), 814-817.

Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., & Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877-881.

Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9
Sagrieya, H., Berube, C., Wen, A., Ramakrishnan, R., Mir, A., & Altman, R. B. (2010). Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. PHARMACOGENETICS AND GENOMICS, 20(7), 407-413.

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
Gotlib, J., Berube, C., Growney, J. D., Chen, C. C., George, T. I., & Coutre, S. E. (2005). Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. BLOOD, 106(8), 2865-2870.